Aliases & Classifications for Impotence

MalaCards integrated aliases for Impotence:

Name: Impotence 12 55 15
Erectile Dysfunction 12 55 43 15 17 72
Erectile Dysfunction Adverse Event 72
Sexual Impotence 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1875
UMLS 72 C0242350 C1961100

Summaries for Impotence

MedlinePlus : 43 Erectile dysfunction (ED) is a common type of male sexual dysfunction. It is when a man has trouble getting or keeping an erection. ED becomes more common as you get older. But it's not a natural part of aging. Some people have trouble speaking with their doctors about sex. But if you have ED, you should tell your doctor. ED can be a sign of health problems. It may mean your blood vessels are clogged. It may mean you have nerve damage from diabetes. If you don't see your doctor, these problems will go untreated. Your doctor can offer several new treatments for ED. For many men, the answer is as simple as taking a pill. Getting more exercise, losing weight, or stopping smoking may also help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Impotence, also known as erectile dysfunction, is related to vasculogenic impotence and hyperprolactinemia, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Impotence is PDE5A (Phosphodiesterase 5A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Calcium signaling pathway. The drugs Fenofibrate and Yohimbine have been mentioned in the context of this disorder. Affiliated tissues include prostate, endothelial and spinal cord, and related phenotypes are endocrine/exocrine gland and reproductive system

Related Diseases for Impotence

Diseases related to Impotence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 572)
# Related Disease Score Top Affiliating Genes
1 vasculogenic impotence 34.2 PDE5A NOS3 ALDH7A1
2 hyperprolactinemia 31.4 VIP SHBG PRL
3 nonarteritic anterior ischemic optic neuropathy 31.1 PDE5A NOS3 EDN1
4 peyronie disease 31.0 PDE5A NOS2
5 gynecomastia 30.9 SHBG PRL KLK3
6 estrogen excess 30.7 SHBG PRL
7 androgenic alopecia 30.6 SHBG PRL KLK3
8 migraine with or without aura 1 30.4 VIP PDE5A EDNRA
9 varicocele 30.3 SHBG PRL NOS3 NOS2
10 hypertension, essential 30.3 NOS3 NOS2 EDNRA EDN1
11 alopecia, androgenetic, 1 30.2 SRD5A1 SHBG
12 prostatic adenoma 30.2 SRD5A1 KLK3
13 psychosexual disorder 30.1 SHBG PDE5A ALDH7A1
14 orthostatic intolerance 30.0 NOS3 NOS2 EDN1
15 portal hypertension 29.8 NOS3 EDNRA EDN1
16 pulmonary hypertension 29.7 VIP PDE5A NOS3 NOS2 EDNRA EDN1
17 prostatic hyperplasia, benign 29.6 SRD5A1 SHBG PDE5A KLK3
18 sexual disorder 29.4 SHBG PRL PDE5A NOS3 NOS1 KLK3
19 multiple system atrophy 1 11.6
20 microvascular complications of diabetes 1 11.6
21 autonomic nervous system disease 11.6
22 autonomic dysfunction 11.5
23 diabetic neuropathy 11.5
24 amyloidosis, hereditary, transthyretin-related 11.3
25 paroxysmal nocturnal hemoglobinuria 1 11.3
26 tabes dorsalis 11.3
27 kallmann syndrome 11.3
28 acth-secreting pituitary adenoma 11.3
29 autosomal dominant leukodystrophy with autonomic disease 11.3
30 familial isolated pituitary adenoma 11.3
31 neuropathy, hereditary sensory and autonomic, type iii 11.2
32 autonomic peripheral neuropathy 11.2
33 empty sella syndrome 11.2
34 tarlov cysts 11.2
35 dysautonomia 11.2
36 lipid metabolism disorder 10.8
37 priapism 10.7
38 hypercholesterolemia, familial, 1 10.7
39 coronary heart disease 1 10.6
40 heart disease 10.6
41 vascular disease 10.6
42 hypogonadism 10.6
43 hypogonadotropism 10.6
44 peyronie's disease 10.5
45 cluster headache 10.5 VIP PRL
46 rhinitis 10.5
47 diabetes mellitus 10.5
48 platelet membrane fluidity 10.5 NOS3 NOS2
49 optic nerve disease 10.5
50 pelvic varices 10.5 SHBG PRL

Graphical network of the top 20 diseases related to Impotence:



Diseases related to Impotence

Symptoms & Phenotypes for Impotence

UMLS symptoms related to Impotence:


tremor, angina pectoris, equilibration disorder, pelvic pain, symptom/complaint potency (excluding p07 p08), inability to maintain erection, unable to perform sex

MGI Mouse Phenotypes related to Impotence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.56 EDN1 EDNRA NOS1 NOS2 NOS3 PRL
2 reproductive system MP:0005389 9.23 KCNMA1 NOS1 NOS2 NOS3 PDE3A PRL

Drugs & Therapeutics for Impotence

Drugs for Impotence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 362)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fenofibrate Approved Phase 4 49562-28-9 3339
2
Yohimbine Approved, Investigational, Vet_approved Phase 4 146-48-5 8969
3
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
4
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
5
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
6
Allantoin Approved Phase 4 97-59-6 204
7
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
8
Zinc Approved, Investigational Phase 4 7440-66-6 32051
9
Magnesium oxide Approved Phase 4 1309-48-4 14792
10
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
11
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
14
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
17
Racepinephrine Approved Phase 4 329-65-7 838
18
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
19
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
20
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
21
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
22
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
23
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
24
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
25
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
26
Methyltestosterone Approved Phase 4 58-18-4 6010
27
Testosterone enanthate Approved Phase 4 315-37-7 9416
28
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
29
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
30
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
31 Lipid Regulating Agents Phase 4
32 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
33 Anticholesteremic Agents Phase 4
34 Antimetabolites Phase 4
35 Immunosuppressive Agents Phase 4
36 Immunologic Factors Phase 4
37 Adrenergic alpha-2 Receptor Antagonists Phase 4
38 Mydriatics Phase 4
39 Peripheral Nervous System Agents Phase 4
40 Yohimbe Phase 4
41 Calcineurin Inhibitors Phase 4
42 Antihypertensive Agents Phase 4
43 arginine Phase 4
44 insulin Phase 4
45 Insulin, Globin Zinc Phase 4
46 Angiotensinogen Phase 4
47 Angiotensin II Type 1 Receptor Blockers Phase 4
48 Giapreza Phase 4
49 Angiotensin Receptor Antagonists Phase 4
50 Adrenergic Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 666)
# Name Status NCT ID Phase Drugs
1 Observational Study to Evaluate the Effect of Tadalafil 5mg Once Daily on Erectile Dysfunction and QOL in Andropause Patients With Erectile Dysfunction Unknown status NCT02943356 Phase 4 Tadalafil
2 Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction: Non- Inferiority, Randomized, Crossover, Open Clinical Trial Unknown status NCT03169582 Phase 4 Avanafil;Sildenafil
3 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
4 Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate i.m. 1000 mg. A Prospective, Multi-Center Clinical Study Phase IV. Unknown status NCT00555087 Phase 4 Testosterone Undecanoate and/or PDE-5
5 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
6 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT01364701 Phase 4 Sildenafil 100 mg;Tadalafil 20 mg;Combination half of maximal dose for sildenafil & tadalafil
7 Nebivolol Effects on Endothelial Function and Erectile Function in Non-smoking Pre-hypertensive and Newly Diagnosed Stage 1 Hypertensive Men With Erectile Dysfunction. Unknown status NCT01885988 Phase 4 Nebivolol;Sugar Pill
8 Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
9 Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial Unknown status NCT01770340 Phase 4
10 The Effect of Treatment for ED on Quality of Life and Satisfaction in a Group of Patients Without Prior Complaints of Sexual Dysfunction Unknown status NCT00313898 Phase 4 sildenafil (viagra)
11 Effect of Fenofibrate and Rosuvastatin on Sexual Dysfunction in Hyperlipidemic Patients. A Randomized Trial Unknown status NCT00923676 Phase 4 fenofibrate;Rosuvastatin;fenofibrate + rosuvastatin
12 Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure Unknown status NCT00793338 Phase 4 Sildenafil
13 Multicenter Randomized Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose - II Completed NCT00143260 Phase 4 Viagra (Sildenafil Citrate) 100 mg
14 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study of Men With Mild to Moderate Erectile Dysfunction to Evaluate the Efficacy of Viagra 8 Hours Post-Dose Completed NCT00137072 Phase 4 Viagra (Sildenafil Citrate) 100 mg
15 Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction (ED) Patients Previously Treated With Other Oral ED Therapy Completed NCT00422578 Phase 4 tadalafil
16 Tadalafil Once Daily Following As-Needed Phosphodiesterase Type 5 Inhibitor Treatment, an Assessment of Return to Normal Erectile Function Completed NCT01130532 Phase 4 Tadalafil;Placebo
17 An Open Label, Multicenter Study to Measure Treatment Responsiveness of Quality of Sexual Life Questionnaire in the Female Partner of Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) Completed NCT00245596 Phase 4 sildenafil
18 An Evaluation of Semen Characteristics After 40 Weeks Daily Dosing With 20 mg Tadalafil Completed NCT00382135 Phase 4 tadalafil;placebo
19 A Randomized, Double Blind, Placebo-controlled, Parallel Group, Multi-center Study to Investigate the Responsiveness of the Erectile Quality Scale (EQS) to Vardenafil HCl Flexible Dose Versus Placebo in Males With Erectile Dysfunction. Completed NCT00665340 Phase 4 Placebo;Levitra (Vardenafil, BAY38-9456)
20 Does Presence of Distress Due to Erectile Dysfunction Affect the Effect of Tadalafil on Sexual Life and Life Satisfaction? Completed NCT00547599 Phase 4 tadalafil
21 A Prospective Multicenter, Parallel Group Study With A Single Blind Phase And A Double Blind Randomised Phase, To Evaluate The Efficacy And Satisfaction Of Viagra (Sildenafil Citrate) High Dose (100mg) Titration Compared With 50mg Dose, In Men With Erectile Dysfunction Completed NCT00249730 Phase 4 Sildenafil
22 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Flexible Dose Study With and Open-Label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
23 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia Completed NCT00379756 Phase 4 LEVITRA (vardenafil);placebo
24 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia. Completed NCT00663845 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
25 A Multicenter, Double-Blind Placebo Controlled, Fixed Dose Study With An Open-Label, Flexible Dose Phase To Assess The Efficacy Of Sildenafil Citrate In Providing A Better Sexual Experience Including Quality Of Erections And Satisfaction In Men With Erectile Dysfunction Completed NCT00245258 Phase 4 Sildenafil Citrate
26 A Multi-Center, Double-Blind Placebo Controlled, Flexible-Dose Study With An Open-Label Phase To Assess The Efficacy Of Sildenafil Citrate On Erectile Function And Intercourse Satisfaction As Well As To Validate The Sexual Experience Questionnaire And Its Treatment Responsiveness In Men With Erectile Dysfunction Completed NCT00147628 Phase 4 sildenafil citrate;placebo for sildenafil citrate
27 Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference Completed NCT00547352 Phase 4 tadalafil;sildenafil
28 A Multi-Center, Parallel Group, Flexible Dose Trial With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Assess The Impact Of Viagra On The Sexual Satisfaction Of Men With Mild Erectile Dysfunction Completed NCT00301262 Phase 4 Viagra (Sildenafil citrate)
29 A Randomized, Double Blind, Parallel Group Study of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction and Their Female Partners Sexual Quality of Life. PARTNER II Completed NCT00377793 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
30 The Use and Efficacy of Sildenafil in Diabetic Men With Erectile Dysfunction: the Impact on Endothelial Function, a Pilot Feasibility Study Completed NCT00199563 Phase 4 Viagra
31 A Multicenter Open-Label Study to Determine Treatment Preference of Tadalafil (IC351, LY450190) or Sildenafil Citrate in the Oral Treatment of Erectile Dysfunction Completed NCT00547092 Phase 4 tadalafil;sildenafil
32 A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Flexible-Dose Study To Assess The Efficacy And Safety Of Viagra (Sildenafil Citrate) In Men With Erectile Dysfunction (ED) Who Do Not Self Identify. Completed NCT00343200 Phase 4 Placebo;Viagra (sildenafil citrate)
33 REALISE Levitra® - Real Life Safety and Efficacy of Levitra Completed NCT00663598 Phase 4 Levitra (Vardenafil, BAY38-9456)
34 A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Prograf (Tacrolimus, FK 506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-sparing Radical Prostatectomy Completed NCT00106392 Phase 4 Tacrolimus;Placebo
35 An Open-label, Multi-center, Factorial Design, Cluster-randomized Clinical Study of Vardenafil in Canadian Males With Erectile Dysfunction: Impact of Education of the Primary Care Physician and Patient on Patient Outcomes. Completed NCT00664833 Phase 4
36 A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men With Erectile Dysfunction Completed NCT01698684 Phase 4 Placebo;Avanafil 100 mg;Avanafil 200 mg
37 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Clinical Trial of the Effect of Avanafil (STENDRA™) on Spermatogenesis in Healthy Adult Males and Adult Males With Mild Erectile Dysfunction Completed NCT01768676 Phase 4 avanafil;Placebo
38 Tadalafil 2.5 mg and 5 mg Once a Day Compared to Placebo in Day of Onset of Efficacy Completed NCT00833638 Phase 4 Placebo;Tadalafil
39 Randomised, Double Blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Study to Evaluate the Efficacy and Tolerability of Vardenafil (BAY 38-9456) in Treatment of Male Erectile Dysfunction in Asia Completed NCT00668135 Phase 4 Vardenafil (Levitra, BAY38-9456);Placebo
40 A Rand, db, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Plac in Men With Diabetes Mellitus Type 1 and Erectile Dysfunction Completed NCT00660998 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
41 Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naïve to PDE5 Inhibitors Completed NCT01122264 Phase 4 Tadalafil;Sildenafil Citrate
42 Multi-centre, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Assess the Efficacy and Tolerability of Vardenafil and Its Influence on Self-esteem and Self Confidence in Subjects With Erectile Dysfunction. Completed NCT00665054 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
43 Open-Label, Multi-Centre, Study of Levitra 10 mg Once a Day in Males With Erectile Dysfunction Was Carried Out in Four Centres Namely Lagos, Port Harcourt, Enuge and Maiduguri at Their University Teaching Hospitals Completed NCT00662441 Phase 4 Levitra (Vardenafil, BAY38-9456)
44 A Randomised, Double-blind, Double-dummy, Parallel-group, Active-controlled Study Evaluating the Efficacy of Vardenafil Versus Tadalafil When Intercourse is Attempted Within 45 Minutes of Administration in Subjects With Erectile Dysfunction Completed NCT00663130 Phase 4 Levitra (Vardenafil, BAY38-9456);Tadalafil
45 Postmarketing Surveillance Study: A Randomized, Open-Label, 3-Month Interventional Study of Tadalafil Effectiveness (2.5 mg and 5 mg) and Long-Term Safety Administered Once Daily in Chinese Men With Erectile Dysfunction Completed NCT02224846 Phase 4 Tadalafil
46 An Evaluation of Tadalafil and Sildenafil Treatment in Men With Erectile Dysfunction in China Completed NCT01352507 Phase 4 Tadalafil;Sildenafil
47 Double-blind, Placebo Controlled, Randomized Study of Vardenafil to Determine Efficacy on Erectile Dysfunction (ED) in Men With ED and Metabolic Syndrome (ED-METABOLIC) Completed NCT00738400 Phase 4 Vardenafil (Levitra, BAY38-9456);Placebo
48 A Randomized, Double Blind, Placebo Controlled, Flexible Dose, Multicentre Study of Levitra in a Broad Population of Men With Erectile Dysfunction and Previously Untreated With PDE5 Inhibitors. Completed NCT00668096 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
49 Open-label, Multi-centre, Study to Investigate the Safety, Tolerability and Efficacy of Flexible Doses of Vardenafil Given on Demand in Males With Erectile Dysfunction Completed NCT00681772 Phase 4 Levitra (Vardenafil, BAY38-9456)
50 A Randomized, Double-blind, Placebo Controlled, Parallel Arm, Multicenter Trial Assessing the Effect of Daily Treatment of Vardenafil 20 mg or Sildenafil 100 mg Compared to Placebo on Spermatogenesis Completed NCT00655590 Phase 4 Levitra (Vardenafil, BAY38-9456);Sildenafil;Placebo

Search NIH Clinical Center for Impotence

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Alprostadil
Avanafil
Ginseng Preparation
Methyltestosterone
METHYLTESTOSTERONE PWDR
Papaverine
Papaverine Hydrochloride
Sildenafil
Tadalafil
Vardenafil
yohimbine
Yohimbine hydrochloride

Genetic Tests for Impotence

Anatomical Context for Impotence

MalaCards organs/tissues related to Impotence:

41
Prostate, Endothelial, Spinal Cord, Testes, Heart, Smooth Muscle, Kidney

Publications for Impotence

Articles related to Impotence:

(show top 50) (show all 19578)
# Title Authors PMID Year
1
Re: Updated Evidence of Association between Periodontal Disease and Incident Erectile Dysfunction. 38 17
31009980 2019
2
Re: Erectile Dysfunction Severity as a Predictor of Left Main and/or Three-Vessel Disease in Acute Coronary Syndrome Patients. 38 17
31009962 2019
3
Re: Penile Prosthesis Reservoir Removal: Surgical Description and Patient Outcomes. 17
31009963 2019
4
Toxicological evaluation of a dietary supplement formulated for male sexual health prior to market release. 9 38
20043970 2010
5
Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. 9 38
20402554 2010
6
T-786C polymorphism in promoter of eNOS gene as genetic risk factor in patients with erectile dysfunction in Turkish population. 9 38
19800665 2010
7
Adaptive spaced education improves learning efficiency: a randomized controlled trial. 9 38
20022032 2010
8
Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction. 9 38
19907424 2010
9
Pharmacotherapy for erectile dysfunction. 9 38
20092451 2010
10
Ten-year follow-up of sildenafil use in spinal cord-injured patients with erectile dysfunction. 9 38
19686427 2009
11
Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. 9 38
19884625 2009
12
[Efficacy and safety of tadalafil for erectile dysfunction: an updated review]. 9 38
20112748 2009
13
Is penile length a factor in treatment of erectile dysfunction with PDE-5 inhibitor? 9 38
19234311 2009
14
Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. 9 38
19701217 2009
15
Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. 9 38
19210710 2009
16
Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. 9 38
19387454 2009
17
Association of coronary artery disease, erectile dysfunction, and endothelial nitric oxide synthase polymorphisms. 9 38
19466514 2009
18
Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. 9 38
19377497 2009
19
EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor. 9 38
19036180 2009
20
In men with erectile dysfunction, satisfaction with quality of erections correlates with erection hardness, treatment satisfaction, and emotional well-being. 9 38
19143914 2009
21
[Psychosis and sexuality]. 9 38
19365914 2009
22
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. 9 38
19138360 2009
23
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils. 9 38
19010346 2009
24
Aspects of sexual satisfaction in men with erectile dysfunction: a factor analytic and logistic regression approach. 9 38
19170852 2009
25
Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. 9 38
19125990 2009
26
PDE5 inhibitors in non-urological conditions. 9 38
19860698 2009
27
Online spaced education to teach urology to medical students: a multi-institutional randomized trial. 9 38
18614145 2009
28
[Tadalafil for erectile dysfunction: excellent safety and tolerance]. 9 38
19288756 2009
29
Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction. 9 38
18976905 2008
30
New treatments for localized prostate cancer. 9 38
19095127 2008
31
The role of combination medical therapy in benign prostatic hyperplasia. 9 38
19002123 2008
32
5-alpha reductase inhibitors and erectile dysfunction: the connection. 9 38
19090946 2008
33
Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction. 9 38
18528398 2008
34
Recreational use of PDE5 inhibitors by young healthy men: recognizing this issue among medical students. 9 38
18331258 2008
35
Pulmonary embolism after tadalafil ingestion. 9 38
18548330 2008
36
The effect of 5 alpha-reductase inhibitors on erectile function. 9 38
18421068 2008
37
[Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours]. 9 38
18998474 2008
38
Potent inhibition of human phosphodiesterase-5 by icariin derivatives. 9 38
18778098 2008
39
Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicine. 9 38
18674473 2008
40
Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. 9 38
18644193 2008
41
Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. 9 38
18395326 2008
42
A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. 9 38
18281145 2008
43
Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial. 9 38
18423715 2008
44
Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction. 9 38
18385912 2008
45
[Expressions of eNOS and connexin 43 in the penile tissue of rats with diabetic erectile dysfunction]. 9 38
18572862 2008
46
[Type V phosphodiesterase inhibitor erection-provoking test with audio-visual sexual stimulation for the diagnosis of erectile dysfunction]. 9 38
18572866 2008
47
Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms. 9 38
18075506 2008
48
The effect of physician and patient education when combined with vardenafil treatment in Canadian males with erectile dysfunction: an open-label, factorial-designed, cluster-randomized clinical trial. 9 38
18304285 2008
49
Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. 9 38
18086159 2008
50
Absence of hypogonadism in a male patient with a giant prolactinoma: a clinical paradox. 9 38
18082643 2008

Variations for Impotence

Expression for Impotence

Search GEO for disease gene expression data for Impotence.

Pathways for Impotence

Pathways related to Impotence according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.11 PDE5A PDE3A NOS3 NOS2 NOS1 KCNMA1
2
Show member pathways
12.11 NOS3 NOS2 NOS1 EDNRA
3
Show member pathways
12.01 PDE5A PDE3A NOS3 NOS2 NOS1 KCNMA1
4 11.88 NOS3 NOS2 NOS1
5 11.76 NOS3 NOS2 EDN1
6 11.55 PDE3A KCNMA1 EDNRA
7
Show member pathways
11.47 NOS3 NOS2 NOS1
8
Show member pathways
11.31 NOS3 NOS2 NOS1 ARG2 ALDH7A1
9
Show member pathways
11.27 NOS3 NOS2 NOS1
10 11.18 NOS3 EDNRA EDN1
11 11.11 PRL EDNRA EDN1
12 11.06 NOS3 NOS2 NOS1
13
Show member pathways
11.04 NOS3 NOS2 NOS1 ARG2
14 10.96 NOS3 NOS2 NOS1
15
Show member pathways
10.72 PDE5A PDE3A NOS3 NOS2 NOS1 KCNMA1
16 10.45 NOS3 NOS2 NOS1
17 10.37 PDE5A NOS3 NOS2 NOS1

GO Terms for Impotence

Cellular components related to Impotence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 caveola GO:0005901 9.13 NOS3 NOS1 KCNMA1
2 vesicle membrane GO:0012506 8.8 NOS3 NOS2 NOS1

Biological processes related to Impotence according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.97 SRD5A1 NOS3 NOS2 NOS1 CYP3A4 ALDH7A1
2 response to drug GO:0042493 9.79 SRD5A1 PDE3A EDN1
3 response to hypoxia GO:0001666 9.77 NOS2 NOS1 KCNMA1 EDNRA EDN1
4 cell redox homeostasis GO:0045454 9.74 NOS3 NOS2 NOS1
5 regulation of blood pressure GO:0008217 9.73 NOS3 EDNRA EDN1
6 response to hormone GO:0009725 9.7 NOS3 NOS2 NOS1
7 positive regulation of cardiac muscle hypertrophy GO:0010613 9.65 PDE5A EDN1
8 exogenous drug catabolic process GO:0042738 9.65 NOS1 CYP3A4
9 neural crest cell development GO:0014032 9.64 EDNRA EDN1
10 vasodilation GO:0042311 9.64 NOS3 NOS1
11 regulation of sodium ion transport GO:0002028 9.63 NOS3 NOS1
12 regulation of blood vessel size GO:0050880 9.63 NOS3 EDN1
13 negative regulation of blood pressure GO:0045776 9.63 NOS3 NOS2 NOS1
14 vasoconstriction GO:0042310 9.62 EDNRA EDN1
15 androgen metabolic process GO:0008209 9.62 SRD5A1 CYP3A4
16 response to lipopolysaccharide GO:0032496 9.62 NOS3 NOS2 NOS1 EDN1
17 striated muscle contraction GO:0006941 9.61 NOS1 ARG2
18 negative regulation of calcium ion transport GO:0051926 9.6 NOS3 NOS1
19 artery smooth muscle contraction GO:0014824 9.59 EDNRA EDN1
20 body fluid secretion GO:0007589 9.58 VIP EDN1
21 nitric oxide mediated signal transduction GO:0007263 9.58 NOS3 NOS2 NOS1
22 regulation of glucose transmembrane transport GO:0010827 9.55 EDNRA EDN1
23 negative regulation of hydrolase activity GO:0051346 9.54 NOS3 NOS1
24 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.51 NOS3 EDN1
25 peptidyl-cysteine S-nitrosylation GO:0018119 9.48 NOS2 NOS1
26 positive regulation of oocyte development GO:0060282 9.43 PDE5A PDE3A
27 positive regulation of guanylate cyclase activity GO:0031284 9.43 NOS3 NOS2 NOS1
28 negative regulation of potassium ion transport GO:0043267 9.33 VIP NOS3 NOS1
29 multicellular organismal response to stress GO:0033555 9.28 NOS1
30 arginine catabolic process GO:0006527 9.13 NOS3 NOS2 NOS1
31 nitric oxide biosynthetic process GO:0006809 8.92 NOS3 NOS2 NOS1 ARG2

Molecular functions related to Impotence according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.85 SRD5A1 NOS3 NOS2 NOS1 CYP3A4 ALDH7A1
2 heme binding GO:0020037 9.71 NOS3 NOS2 NOS1 CYP3A4
3 hormone activity GO:0005179 9.67 VIP PRL EDN1
4 flavin adenine dinucleotide binding GO:0050660 9.65 NOS3 NOS2 NOS1
5 NADP binding GO:0050661 9.61 NOS3 NOS2 NOS1
6 3',5'-cyclic-nucleotide phosphodiesterase activity GO:0004114 9.51 PDE5A PDE3A
7 FMN binding GO:0010181 9.5 NOS3 NOS2 NOS1
8 cadmium ion binding GO:0046870 9.46 NOS3 NOS1
9 arginine binding GO:0034618 9.43 NOS3 NOS2 NOS1
10 NADPH-hemoprotein reductase activity GO:0003958 9.33 NOS3 NOS2 NOS1
11 3',5'-cyclic-GMP phosphodiesterase activity GO:0047555 9.22 PDE5A
12 tetrahydrobiopterin binding GO:0034617 9.13 NOS3 NOS2 NOS1
13 nitric-oxide synthase activity GO:0004517 8.8 NOS3 NOS2 NOS1

Sources for Impotence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....